Results 1 to 10 of about 2,387 (195)

Virus Detection and Hospitalization Rate in Infants With Bronchiolitis After Nirsevimab Introduction: A Retrospective Comparative Two-Season Study. [PDF]

Pediatr Pulmonol
Introduction: Respiratory syncytial virus (RSV) is the leading cause of lower respiratory tract infections (LRTIs) in infants. In 2024, the monoclonal antibody nirsevimab became available in Italy for all newborns during their first RSV season. Aims: The
La Regina DP, Spatuzzo M, Bonci E, Nenna R, Petrarca L, Conti MG, Mancino E, Pierangeli A, Antonelli G, Midulla F.   +9 more
europepmc   +2 more sources

Uptake and predictors of newborn respiratory syncytial virus (RSV) immunisation with nirsevimab in Ireland's national pilot programme: a cross-sectional study. [PDF]

BMJ Open
Masukume G, McMorrow A, Dawood I, Rafdhy K, O'Brien F, Desmond C, O'Connell D, Murphy B, Ronan E, Purtill H, Philip RK.   +10 more
europepmc   +1 more source

Knowledge and Attitudes of Ontario Pediatricians Related to Existing and New Respiratory Syncytial Virus (RSV) Prevention Products: A Cross-Sectional Study. [PDF]

Pediatr Pulmonol
Rose A, Datta RR, Di Chiara C, Piché-Renaud PP, Morris SK.   +4 more
europepmc   +1 more source

Genomic evolution and minority variant dynamics of RSV during the first season of nirsevimab implementation in Italy (2024-5). [PDF]

Virus Evol
Romano G, Campagna R, Ferrari G, Pitrolo AMG, Turriziani O, Fracella M, Coratti E, Cinti L, Roberto P, Petrarca L, Nenna R, Midulla F, Bonetti A, Licari A, Piralla A, Antonelli G, Baldanti F, Pierangeli A.   +17 more
europepmc   +1 more source

Maternal RSV Vaccination, Infant Nirsevimab, or Both: Interim Analysis of a Randomized Trial. [PDF]

Pediatrics
Rostad CA, Healy CM, Nayak JL, Parameswaran L, Creech CB, Martin JM, Brady RC, Jones-Beatty K, Badell M, Eppes C, Quinn M, Mulligan M, Rolsma SL, Rick AM, Forde B, Avadhanula V, Piedra PA, Telu K, Kunwar PS, Mu J, Gao F, Pasetti MF, Flach B, Posavad CM, Miedema J, Piper JM, Kim S, Beresnev T, Cardemil C, Campbell JD, DMID 24-0003 PROMISE Study Group.   +30 more
europepmc   +1 more source

Administration Timing of Respiratory Syncytial Virus Preventatives Among Commercially Insured Populations in the United States: 2024-2025 RSV Season. [PDF]

Vaccines (Basel)
Law AW, Mayer DC, Zakeri M, Yapar N, Passarelli A, Baser O, MacDonald PDM.   +6 more
europepmc   +1 more source

RSV prophylactics for pediatric populations: A product review and meta-analysis of real-world effectiveness. [PDF]

Hum Vaccin Immunother
Oliva IO, Oliveira CR.
europepmc   +1 more source

Impact of a national nirsevimab programme on critical care transport of babies with bronchiolitis: a retrospective observational study. [PDF]

Arch Dis Child
Moore T, Afridi A, Aminudin NH, Gibbons C, Grant O, Fucikova H, Moore CM.   +6 more
europepmc   +1 more source

Dual Immunization Against RSV With RSVpreF and Nirsevimab.

JAMA Pediatr
Tréluyer L, Bertrand M, Gabet A, Jabagi MJ, Kolla E, Olié V, Zureik M, Rachas A.   +7 more
europepmc   +1 more source

Protecting infants from RSV: cost-effectiveness of nirsevimab in a real-world study from Chile. [PDF]

Lancet Reg Health Am
Priante E, Baraldi E.
europepmc   +1 more source